Karyopharm Therapeutics provided preliminary unaudited 2025 total revenue estimates. The company aims to deliver transformative Phase 3 data in 2026, including top-line data from the Phase 3 SENTRY Trial in Myelofibrosis and XPORT-EC-042 Trial in Endometrial Cancer, both scheduled for 2026.
Top-Line Data Expectation
Karyopharm anticipates revealing critical Phase 3 trial data in 2026 from the SENTRY trial in myelofibrosis and the XPORT-EC-042 trial in endometrial cancer.
Revenue Estimates
For 2025, Karyopharm expects approximately $145 million in total revenue, with U.S. XPOVIO (selinexor) net product revenue making up around $115 million.
Product Revenue
The estimated U.S. XPOVIO (selinexor) net product revenue is projected to reach $115 million in 2025.
- Karyopharm's strategic focus for 2026 centers on the potential value creation through the release of pivotal data from critical Phase 3 trials. Positive outcomes from the SENTRY trial have the potential to redefine treatment standards in myelofibrosis, presenting significant market opportunities.
Karyopharm's 2026 projections indicate a strategic positioning for substantial long-term value creation, with the potential to introduce groundbreaking cancer therapies.